TuHURA Biosciences, Inc. (HURA)
1.63
+0.02
(+1.24%)
USD |
NASDAQ |
Nov 06, 16:00
1.66
+0.03
(+1.84%)
After-Hours: 05:08
TuHURA Biosciences EPS Diluted (Quarterly) : -0.1442 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.1442 |
| March 31, 2026 | -0.1256 |
| December 31, 2025 | -0.1233 |
| September 30, 2025 | -0.1402 |
| June 30, 2025 | -0.2138 |
| March 31, 2025 | -0.1536 |
| December 31, 2024 | -0.1417 |
| September 30, 2024 | -3.000 |
| June 30, 2024 | -1.472 |
| March 31, 2024 | -13.92 |
| December 31, 2023 | -8.272 |
| September 30, 2023 | -63.91 |
| June 30, 2023 | -69.03 |
| March 31, 2023 | -68.00 |
| December 31, 2022 | -73.62 |
| September 30, 2022 | -118.56 |
| June 30, 2022 | -145.48 |
| March 31, 2022 | -190.86 |
| December 31, 2021 | -212.57 |
| September 30, 2021 | -430.34 |
| June 30, 2021 | -360.04 |
| March 31, 2021 | -397.13 |
| December 31, 2020 | -381.69 |
| September 30, 2020 | -2322.90 |
| June 30, 2020 | -584.66 |
| Date | Value |
|---|---|
| March 31, 2020 | -300.18 |
| December 31, 2019 | -267.33 |
| September 30, 2019 | -373.73 |
| June 30, 2019 | -1557.55 |
| March 31, 2019 | -1172.32 |
| December 31, 2018 | -1318.10 |
| September 30, 2018 | -1545.08 |
| June 30, 2018 | -1837.15 |
| March 31, 2018 | -2283.75 |
| December 31, 2017 | -2494.45 |
| September 30, 2017 | -3098.90 |
| June 30, 2017 | -3500.00 |
| March 31, 2017 | -3150.00 |
| December 31, 2016 | -2275.00 |
| September 30, 2016 | -4025.00 |
| June 30, 2016 | -5406.80 |
| March 31, 2016 | -2100.00 |
| December 31, 2015 | -4200.00 |
| September 30, 2015 | -2800.00 |
| June 30, 2015 | -531.30 |
| March 31, 2015 | -3500.00 |
| December 31, 2014 | -2100.00 |
| September 30, 2014 | -2800.00 |
| June 30, 2014 | 7057.40 |
| March 31, 2014 | -7072.10 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.305 |
| Alnylam Pharmaceuticals, Inc. | 15.72 |
| Anika Therapeutics, Inc. | -0.0232 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.2674 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.223M |
| Total Expenses (Quarterly) | 9.223M |
| Enterprise Value | 107.09M |
| Earnings Yield | -32.72% |
| Normalized Earnings Yield | -34.33 |